Nic Chahine’s impressive 83% win rate in his options trading endeavors is a testament to the potential profits that can be achieved in the market with the right strategy and approach. He has been able to achieve an average profit of 27% every 20 days without selling covered calls or spreads, which is a remarkable feat considering most traders struggle to even achieve a 27% winning percentage when buying options.
One of the stocks making headlines recently is Sharps Technology Inc. (NASDAQ:STSS), whose shares have seen a significant surge in value. Despite losing over 42% in the past year, the company has entered into agreements with Nephron SC and Nephron Sterile Compounding Centers. These agreements signify changes from earlier transactions that did not close under their original terms. The company signed a five-year Purchase Agreement with Nephron SC and Nephron Sterile, committing to exclusively use Sharps Technology as its pre-filled copolymer syringe manufacturer. The two companies have agreed to purchase a minimum aggregate of approximately $188.5 million worth of syringes from Sharps Technology. In addition, the company has also formed a cooperative selling and distribution agreement with Italy’s Roncadelle Operations.
As a result of these developments, STSS shares have risen by 157% to $0.55. It is important for investors to conduct thorough research and analysis before making any investment decisions, as demonstrated by Nic Chahine’s success with options trading.
For a chance to win $500 in stock or crypto, you can enter your email to receive Benzinga’s ultimate morning update and a free $30 gift card. Benzinga does not provide investment advice, and all rights are reserved.